Figure 3 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors

Statistical analysis of targeted protein quantitation in capivasertib-sensitive (green) and capivasertib-resistant (red) HR⁺PIK3CA-altered breast cancer cell lines. A, Schematic of experimental design for phase II of the study. B, Heatmap of protein concentrations quantified by MRM-MS with hierarchical clustering. C, Cell line sensitivity to capivasertib, expressed as IC₅₀ (D) Protein concentrations in capivasertib-sensitive vs. capivasertib-resistant cells (E) PCA (left) and PLS-DA plot (right). F, Top 22 features ranked by VIP scores, presented with the direction of change in capivasertib-resistant vs. capivasertib cell lines as compared to NCB vs. CB patient tumors.